EXG102 and EXG202 are investigational gene therapy candidates for wet age-related macular degeneration that are in ...
Researchers described the presence of multiple bilateral serous retinal detachments (SRDs) found in 3 women after they used ...
It is noteworthy that patients with mild TBI often report visual issues despite normal results of visual acuity measurements ...
More than 300 patients have been randomized in the SOL-1 Phase 3 trial for OTX-TKI (AXPAXLI, axitinib intravitreal implant).
The authors searched PubMed, Scopus, MEDLINE, ScienceDirect, and ClinicalTrials.gov, and selected studies based on reports ...
Beacon Therapeutics presented 3-month interim safety and efficacy data from the Phase 2 DAWN trial of laru-zova (AGTC-501) for X-linked retinitis pigmentosa (XLRP) at the FLORetina ICOOR 2024 meeting ...
DelveInsight has released a report entitled, “Diabetic Macular Edema Market Insights, Epidemiology, and Market Forecast-2034.″ This report is a detailed look at diabetic macular edema (DME) ...
The acquisition creates a clinical-stage company focused on the development of gene therapy treatments for rare inherited retinal degenerations.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback